1. Search Result
Search Result
Results for "

a-B

" in MedChemExpress (MCE) Product Catalog:

180

Inhibitors & Agonists

5

Fluorescent Dye

30

Biochemical Assay Reagents

6

Peptides

15

Inhibitory Antibodies

14

Natural
Products

21

Recombinant Proteins

7

Isotope-Labeled Compounds

22

Antibodies

9

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148348

    HBV Infection
    AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein .
    AB-836
  • HY-148768

    HBV Inflammation/Immunology
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .
    AB-506
  • HY-150339

    Drug Metabolite Neurological Disease
    AB-INACA is a metabolite of AB-CHMINACA.
    AB-INACA
  • HY-159987

    HBV Infection
    AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research .
    AB-161
  • HY-118894

    DNA/RNA Synthesis
    AB-182 is an aziridine derivative and antitumor agent.AB-182 shows synergistic antitumor effects in conjunction with x-irradiation. Intermediate hydrolysis products of AB-182 may block the repair of x-irradiation-induced breaks in the DNA strands by phosphorylating their free 3'-OH end groups.
    AB182
  • HY-172214

    SARS-CoV Virus Protease Infection
    AB-343 is a selective covalent inhibitor of SARS-CoV-2 M pro, with an IC50 of 8 nM and a Ki of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .
    AB-343
  • HY-120316

    Parasite Infection
    AB3127-C is an anti-mite agent that can be isolated from Streptomyces platensis AB3217. AB3127-C exerts a protection coefficient of 90% at a concentration of 100 μg/mL .
    AB3127-C
  • HY-163149

    HBV Infection
    AB-452, a Dihydroquinolizinone (DHQ) analogue, is a potent and orally active HBV RNA destabilizer. AB-452 inhibits PAPD5/7 proteins in vitro with good in vivo efficacy in a chronic HBV mouse model .
    AB-452
  • HY-115826

    Biochemical Assay Reagents Cancer
    AB-163 is an alkylating agent with anti-tumor activity. AB-163 exerts LD50s of 198 (p.o.) and 159 (i.p.) mg/kg in ICR/Ha male mice and can be utilized in cancer research .
    AB-163
  • HY-149855

    Sigma Receptor Others
    AB10 is a selective S1R antagonist. AB10 with Ki of 10, 165 nM for S1R and S2R, respectively. AB10 reverses the effect of Capsaicin (HY-10448) caused pain in model .
    AB10
  • HY-117241

    Parasite Infection
    AB 3217-B is an analog of AB 3217-A and has anti-mite activity.
    AB 3217-B
  • HY-P990369

    AB3-7

    HCV Inflammation/Immunology
    Anti-CLDN6 Antibody (AB3-7) is a humanized antibody expressed in CHO targeting CLDN6. Anti-CLDN6 Antibody (AB3-7) has an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 78.02 kDa. The isotype control for Anti-CLDN6 Antibody (AB3-7) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN6 Antibody (AB3-7)
  • HY-P990368

    AB1-11

    HCV Inflammation/Immunology
    Anti-CLDN6 Antibody (AB1-11) is a CHO-expressed human antibody that targets CLDN6. Anti-CLDN6 Antibody (AB1-11) has an IgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 78.42 kDa. The isotype control for Anti-CLDN6 Antibody (AB1-11) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-CLDN6 Antibody (AB1-11)
  • HY-171331

    PD-1/PD-L1 Integrin Cancer
    AB-3PRGD2 is a radiotherapeutic agent targeting integrin αvβ3. AB-3PRGD2 shows improved tumor uptake and prolonged tumor retention, leading to significantly enhanced tumor growth suppression. AB-3PRGD2 can remodel the tumor immune microenvironment by upregulating PD-L1 expression and increasing tumor-infiltrating CD8 + T cells .
    AB-3PRGD2
  • HY-155332

    Bacterial Infection
    AB131 is a MSMEG 6649 and Rv2172c inhibitor (Kd: 0.16 and 0.02 μM respectively). AB131 can sensitize the antimycobacterial activity of the antitubercular agent .
    AB131
  • HY-149854

    Sigma Receptor Neurological Disease
    AB21 is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 has the effect of reducing mechanical hypersensitivity .
    AB21
  • HY-149854B

    Sigma Receptor Neurological Disease
    AB21 hydrochloride is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 hydrochloride has the effect of reducing mechanical hypersensitivity .
    AB21 hydrochloride
  • HY-162859

    DNA/RNA Synthesis Cancer
    AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC50 value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .
    AB25583
  • HY-P991292

    ADC Antibody Cancer
    AB-3A4 is a human IgG1 monoclonal antibody (mAb) targeting KAAG1. AB-3A4 can be used in the study of ovarian cancer, triple-negative breast cancer, and prostate cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    AB-3A4
  • HY-171183

    Microtubule/Tubulin Apoptosis Cancer
    AB8939 is an effective small moleculeMicrotubule/Tubulin polymerization inhibitor with anti-tumor activity (it inhibits tumor cell proliferation with an IC50 of less than 10 nM). AB8939 can effectively evade resistance mechanisms mediated by things like P-glycoprotein and myeloperoxidase. AB8939 can induce G2/M phase cell cycle arrest and apoptosis in cells .
    AB8939
  • HY-10209A
    Masitinib mesylate
    5+ Cited Publications

    AB-1010 mesylate

    c-Kit PDGFR Src FGFR Apoptosis Cancer
    Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib mesylate
  • HY-P990326

    Ab-14E1

    TGF-β Receptor Inflammation/Immunology
    Anti-ACVR2A Antibody (Ab-14E1) is a CHO-expressed human antibody that targets ACVR2A. Anti-ACVR2A Antibody (Ab-14E1) features an IgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-ACVR2A Antibody (Ab-14E1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-ACVR2A Antibody (Ab-14E1)
  • HY-19365
    AB-MECA
    1 Publications Verification

    Adenosine Receptor Neurological Disease
    AB-MECA is a high affinity A3 adenosine receptor agonist with a binding Ki of 430.5 nM for human A3 receptors in CHO cells. AB-MECA can enhance plasma histamine level .
    AB-MECA
  • HY-W709579

    Drug Metabolite Others
    AB-CHMINACA metabolite M5A is a metabolite of AB-CHMINACA in the liver.
    AB-CHMINACA metabolite M5A
  • HY-117403

    Cannabinoid Receptor Potassium Channel
    AB-FUBICA (Compound 13) is a CB1 and CB2 receptor agonist that activates G-protein coupled inwardly rectifying potassium channels (GIRK) by binding to CB1 and CB2 receptors, displaying notable cannabinoid-like activity. AB-FUBICA has EC50 values of 21 nM for CB1 and 15 nM for CB2. AB-FUBICA may be suitable for studying pain management, neurodegenerative diseases, and inflammation-related mechanisms .
    AB-FUBICA
  • HY-125286
    AB-680
    10+ Cited Publications

    CD73 Cancer
    AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680
  • HY-149854A

    Sigma Receptor Neurological Disease
    AB21 oxalate is a potent and selective S1R antagonist with Kis of 13, 102 nM for S1R and S2R. AB21 oxalate has the effect of reducing mechanical hypersensitivity .
    AB21 oxalate
  • HY-117986

    Antibiotic AB3217A

    Parasite Infection
    AB 3217-A, an anti-mite substance, can be isolated from the fermentation broth of a streptomycete strain .
    AB 3217-A
  • HY-P990030

    AB-308

    Transmembrane Glycoprotein Infection Inflammation/Immunology
    Ralzapastotug (AB-308) is an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) IgG1 monoclonal antibody. Ralzapastotug is a monoclonal antibody targeting amino acids 106-126 of the cellular prion protein PrP C .
    Ralzapastotug
  • HY-125286A

    CD73 Cancer
    AB-680 ammonium is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73, displays >10,000-fold selectivity over related ecto-nucleotidases CD39. Anti-tumor activity .
    AB-680 ammonium
  • HY-116077

    Others Others
    AB 5046B is a chlorosis-inducing substance can be isolated from Nodulisporium sp .
    AB 5046B
  • HY-W714366

    Isotope-Labeled Compounds Others
    AB-CHMINACA metabolite M4-d4 is deuterium labeled AB-CHMINACA metabolite M4 .
    AB-CHMINACA metabolite M4-d4
  • HY-10209AR

    AB-1010 mesylate (Standard)

    Reference Standards c-Kit PDGFR Src FGFR Apoptosis Cancer
    Masitinib (mesylate) (Standard) is the analytical standard of Masitinib (mesylate). This product is intended for research and analytical applications. Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib mesylate (Standard)
  • HY-112142
    AB-423
    3 Publications Verification

    (R)-DVR-23

    HBV Infection
    AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells.
    AB-423
  • HY-W293109

    Drug Metabolite Others
    AB-PINACA 3-Carboxyindazole metabolite is a metabolite of APINAC.
    AB-PINACA 3-Carboxyindazole metabolite
  • HY-117980

    AB 132

    DNA/RNA Synthesis Cancer
    Meturedepa (AB 132) functions as a radiation sensitizer, enhancing the biological effects of radiation. When combined with suboptimal doses of X-ray radiation, this combined therapy achieves better outcomes in terms of tumor shrinkage compared to Meturedepa used alone. Meturedepa is applicable in the research of bronchogenic carcinoma .
    Meturedepa
  • HY-P1698

    AB-103

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-10209
    Masitinib
    5+ Cited Publications

    AB1010

    c-Kit PDGFR Src FGFR FAK Apoptosis Cancer
    Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib
  • HY-P99047

    AB 0024; GS 6624

    Monoamine Oxidase Inflammation/Immunology Cancer
    Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab can be used for the research of primary sclerosing cholangitis (PSC) .
    Simtuzumab
  • HY-170390

    PROTACs Epigenetic Reader Domain Cancer
    AB3067 is a PROTAC degrader for BET protein, that recruits two different E3 ligase Cereblon and VHL with good affinity (IC50=559 nM for VHL in live HEK293; IC50=190 nM for CRBN in live HEK293), and degrades BRD2, BRD3, BRD4 and CRBN with DC50 of 2.1~2.3, 1.6, 15 and 75 nM, respectively. AB3067 inhibits the proliferation of RKO cell with an EC50 of 111 nM . (Pink: ligand for target protein (HY-131633A); Black: linker (HY-170391); Blue: ligand for E3 ligase VHL (HY-112078) and CRBN(HY-W998346))
    AB3067
  • HY-145594
    Safusidenib
    1 Publications Verification

    AB-291; DS-1001

    Isocitrate Dehydrogenase (IDH) Cancer
    Safusidenib (AB-291; DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma . Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively .
    Safusidenib
  • HY-159644

    AB521

    HIF/HIF Prolyl-Hydroxylase Cancer
    Casdatifan (AB521) is an orally active HIF-2α (hypoxia-inducible factor 2α) inhibitor. Casdatifan exhibited significant antitumor activity and favorable pharmacokinetics in ccRCC (clear cell renal cell carcinoma) models .
    Casdatifan
  • HY-129393
    Etrumadenant
    5+ Cited Publications

    AB928

    Adenosine Receptor Inflammation/Immunology Cancer
    Etrumadenant (AB928) is an orally bioavailable, selective dual adenosine receptor (A2aR/A2bR) antagonist. Etrumadenant relieves adenosine-mediated immune suppression. Etrumadenant has immunomodulatory and antitumor activities .
    Etrumadenant
  • HY-P99858

    AB154

    Transmembrane Glycoprotein Cancer
    Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
    Domvanalimab
  • HY-P1698B

    AB-103 TFA

    Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-176205

    AB801

    TAM Receptor Cancer
    Ligritinib (AB801) is an orally active AXL receptor tyrosine kinase inhibitor. Ligritinib blocks the downstream signaling pathway by inhibiting the kinase activity of AXL. Ligritinib can be used in cancer research, especially in combination with chemotherapy for non-small cell lung cancer (NSCLC) .
    Ligritinib
  • HY-114880

    Cannabinoid Receptor Neurological Disease
    AB-FUBINACA 3-fluorobenzyl isomer is a synthetic cannabinoid that belongs to the indole derivatives and has a high affinity for the central CB1 receptors (Ki= 0.9 nM), exhibiting anticonvulsant activity .
    AB-FUBINACA 3-fluorobenzyl isomer
  • HY-10209R

    AB1010 (Standard)

    Reference Standards c-Kit PDGFR Src FGFR FAK Apoptosis Cancer
    Masitinib (Standard) is the analytical standard of Masitinib. This product is intended for research and analytical applications. Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .
    Masitinib (Standard)
  • HY-113945

    Antibiotic Bacterial Infection
    Abbeymycin is an antibiotic derived from the actinobacterium Streptomyces sp. AB-999F-52. Abbeymycin is a specifically acting antibiotic with antimicrobial activity, primarily targeting anaerobic bacteria. Abbeymycin is employed in research concerning antibiotic discovery and screening .
    Abbeymycin
  • HY-D0402

    AB26

    Fluorescent Dye
    Acid black 26 is a black agent whose coloring effect can be removed by adsorbents such as zeolites.
    Acid black 26

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: